Alexander I. Spira, MD, PhD, FACP, FASCO

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss ongoing research in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss safety and toxicity management in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss the significance of the FDA approval of subcutaneous amivantamab in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss trial data informing amivantamab use in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss how NCCN Guidelines can influence treatment decisions in EGFR-mutated NSCLC.

Luis Raez, MD, FACP, FCCP, and Alexander I. Spira MD, PhD, FACP, FASCO, discuss frontline treatment selection in EGFR-mutated NSCLC.

Experts discuss the potential of amivantamab and velertinib in early-stage lung cancer treatment, emphasizing the need for careful patient management.

Alexander I. Spira, MD, PhD, FACP, FASCO, discusses the FDA approval of subcutaneous amivantamab for patients with EGFR-mutated NSCLC.

Subcutaneous amivantamab offers significant advantages over IV administration, including reduced infusion reactions and quicker patient turnover in clinics.

Subcutaneous amivantamab offers significant advantages over IV administration, including reduced infusion reactions and quicker patient turnover in clinics.

Explore the impact of CNS metastasis on prognosis in EGFR mutant lung cancer and the promising results from the MARIPOSA trial.

The FDA-approved combination of amivantamab and lazertinib transforms frontline treatment for EGFR-mutated lung cancer, enhancing patient outcomes and convenience.

The FDA approval of amivantamab and lazertinib transforms frontline treatment for EGFR-mutated lung cancer, enhancing patient outcomes and convenience.

Experts explore the evolving standards of care for EGFR-mutated advanced NSCLC, highlighting therapy selection and innovative combination strategies.